Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

TEAC and ATTAC immunooncology compositions and methods

A technology of immune cells and tumor antigens, applied in chemical instruments and methods, drug combinations, anti-tumor drugs, etc., can solve problems such as cytokine release syndrome and death

Pending Publication Date: 2022-04-15
THE GENERAL HOSPITAL CORP +1
View PDF11 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

When more T cells are activated, this can lead to greater problems, including cytokine release syndrome (CRS) and, in rare cases, death

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • TEAC and ATTAC immunooncology compositions and methods
  • TEAC and ATTAC immunooncology compositions and methods
  • TEAC and ATTAC immunooncology compositions and methods

Examples

Experimental program
Comparison scheme
Effect test

Embodiment approach

[0459] The following numbered items provide embodiments as described herein, but the embodiments cited here are not limiting.

[0460] Item 1. A medicament for treating cancer in a patient, comprising: a first component comprising a targeted T cell engaging agent comprising: binding to a tumor expressed by the cancer a first targeting moiety of an antigen; a first T cell engaging domain capable of T cell engaging activity when it binds a second T cell engaging domain, wherein the second T cell engaging domain is not part of the first component, and wherein said first T cell engaging domain comprises a VH domain or a VL domain; for a first inert binding partner of the first T cell engaging domain, the first inert binding partner binds to the first T cell engaging domain, such that the first T cell engaging domain does not bind to the second T cell engaging domain unless an inert binding partner is removed, wherein if the first T cell engaging domain comprises a VH domain, the i...

Embodiment 1

[0556] Example 1. Anti-CD33 / anti-CD123 TEACs comprising half-life extending moieties

[0557] A two-component dual IgG TEAC was developed, where each component of the two-component system contained an IgG TEAC. Dual IgG TEACs were designed to contain a first component, an IgG TEAC comprising two targeting moieties, each an anti-CD33 antibody, and a second component, is an IgG TEAC comprising two targeting moieties, each of which is an anti-CD123 antibody. Each IgG TEAC also contained two copies of the T cell engagement domain, two copies of the inert binding partner, and two copies of the cleavage site between the T cell engagement domain and the inert binding partner.

[0558] Additionally, both the first and second components together comprise a linker comprising a half-life extending moiety. The half-life extending moiety comprises an Fc domain from IgG4, wherein the Fc domain is directly linked to an inert binding partner. When expressed in HEK293T cells, one copy of TE...

Embodiment 2

[0568] Example 2. Anti-EpCAM TEACs comprising half-life extending moieties

[0569] A variety of TEACs with half-life extending moieties can be designed with EpCAM targeting moieties.

[0570] Design of a two-component dual IgG TEAC comprising a first IgG TEAC comprising two targeting moieties, each an anti-EpCAM antibody, and a second IgG TEAC comprising two targeting moieties , each an anti-EpCAM antibody. Each IgG TEAC also contained two copies of a T cell engaging domain, two copies of an inert binding partner, and two copies of a protease cleavage site between each T cell engaging domain and its inert binding partner.

[0571] Additionally, both the first and second components further comprise a linker comprising a half-life extending moiety (SEQ ID NO: 201 and 202). The half-life extending moiety comprises an Fc domain where one end of the linker is directly linked to an inert binding partner. When expressed in HEK293T cells, one TEAC (EpCAM binding region (scFv) – an...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present disclosure provides a targeted T cell cement (TEAC) and an antibody tumor targeting assembly complex (ATTAC) for targeting cancer. The TEACs or ATTACs described herein may have, for example, a longer half-life or comprise multiple components in a single agent.

Description

[0001] priority claim [0002] This application claims the benefit of U.S. Provisional Application No. 62 / 841,960, filed May 2, 2019. The entire contents of the above are incorporated herein by reference. [0003] sequence listing [0004] This application submits a sequence listing in electronic format. This sequence listing is provided as a file named "2020-04-09_01131-0026-00PCT_ST25.txt" created on April 9, 2020, and its size is 298,657 bytes. The information in electronic format of this Sequence Listing is incorporated herein by reference in its entirety. technical field [0005] The present application relates to targeted T-cell engaging agent (targeted T-cell engaging agent, TEAC) and antibody tumor-targeting assembly complex (antibody tumor-targeting assembly complex, ATTAC) for the treatment of cancer. [0006] A TEAC or ATTAC described herein may have, for example, a longer half-life or comprise multiple components in a single agent. Background technique [00...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): C07K16/28C07K16/30A61K39/00
CPCC07K16/2809C07K16/2812C07K16/2815C07K16/30C07K2317/31C07K2317/60A61K2039/505A61K47/643A61K47/6807A61K47/6851A61K47/60A61K47/6803A61K47/644A61K47/6849A61K47/6813A61P35/00
Inventor M·科伯德M·普莱尔A·科尔萨特
Owner THE GENERAL HOSPITAL CORP
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com